Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 80/100

Failure Rate

40.0%

2 terminated/withdrawn out of 5 trials

Success Rate

50.0%

-36.5% vs industry average

Late-Stage Pipeline

20%

1 trials in Phase 3/4

Results Transparency

50%

1 of 2 completed trials have results

Key Signals

1 with results

Enrollment Performance

Analytics

Phase 2

3(75.0%)

Phase 4

1(25.0%)

4Total

Phase 2(3)

Phase 4(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials

NCT00496873Phase 2Completed

Evaluation of the Safety and Efficacy of Nipent, Cytoxan, and Rituxan

Role: collaborator

NCT02749838Unknown

Characterization of Human Cancers by Molecular Profiling of Patient Biospecimens

Role: lead

NCT02749825Phase 4Terminated

Comparison of Trelstar Versus Lupron or Zoladex in Advanced Prostate Cancer

Role: lead

NCT00766246Phase 2Terminated

Phase II Avastin Trial for Stage IIIB/IV NSCLC

Role: lead

NCT00831597Phase 2Completed

Bendamustine Combined With Rituximab for Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Role: lead

All 5 trials loaded